Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE−/−–LDLR−/− Double-Knockout Mice
| Autor: | Manami Yoshimura, Kanae Hyodo, Tomohide Sanda, Tsutomu Yamashita, Hiromitu Ishii |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Apolipoprotein E
TAFI medicine.medical_treatment PAI-1 Dabigatran etexilate 030204 cardiovascular system & hematology Pharmacology Tissue plasminogen activator Dabigatran 03 medical and health sciences 0302 clinical medicine Thrombin Fibrinolysis Internal Medicine medicine 030212 general & internal medicine business.industry Anticoagulants Thrombolysis Atherosclerosis Original Article Cardiology and Cardiovascular Medicine business Plasminogen activator medicine.drug Lipoprotein |
| Zdroj: | Korean Circulation Journal |
| ISSN: | 1738-5555 1738-5520 |
| Popis: | Background and objectives Atherosclerosis is characterized by a hypercoagulable state, during which coagulation and fibrinolytic factors are activated simultaneously. However, details regarding the thrombolytic pathway in this context remain unknown. Here we investigated how direct long-term inhibition of thrombin influenced spontaneous thrombolytic activity during atherosclerotic progression in apolipoprotein E (ApoE)⁻/⁻-low density lipoprotein receptor (LDLR)⁻/⁻ double-knockout mice. Methods All mice received either standard chow (placebo group) or dabigatran-containing chow for 22 weeks, after which we evaluated them. The amount of atherosclerosis was estimated as the ratio of the atherosclerotic area to the total aortic intimal area. In addition, we used immunohistochemistry to analyze the expression of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), and endothelial nitric oxide synthase (eNOS) in atherosclerotic regions. To evaluate thrombolysis, we used a He-Ne laser to induce thrombosis in vessels of the cremaster muscle and then measured the thrombus volume over time. Results The atherosclerotic area was smaller and thrombolytic activity greater in the dabigatran-treated group than in the placebo group. Furthermore, according to the thrombolysis model, spontaneous thrombolytic activity was increased in the dabigatran-treated mice compared with the placebo mice. In support of these results, immunohistochemistry demonstrated decreased expression of PAI-1 and TAFI but increased expression of eNOS in the dabigatran group compared with the placebo group. However, t-PA expression did not differ between groups. Conclusions Direct long-term inhibition by dabigatran etexilate of thrombin led to an increase in spontaneous thrombolytic activity decreasing the expression of PAI-1 and TAFI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|